This study is a registry for women with Pompe disease (Glycogen Storage Disease Type II, a rare genetic disorder) who are pregnant or have recently been pregnant. It aims to understand pregnancy outcomes, including any complications and how babies grow, for women with Pompe disease. This includes women who are receiving enzyme replacement therapy (ERT) with alglucosidase alfa or avalglucosidase alfa, as well as those who are not. Researchers will follow the mothers' pregnancies for about 10 months and then follow their babies for 3 years after birth. To join, you must already be enrolled in the Pompe registry (NCT00231400) and be pregnant or have documentation of a past pregnancy. The study is currently unclear on its recruitment status.

Study design

This is an observational study, meaning no experimental treatment is given. It is designed to track pregnancy outcomes for women with Pompe disease.

What's involved

You would undergo clinical assessments and receive standard of care treatment as determined by your physician. Data collection would be performed after you provide signed consent.

Compensation

Not stated in the trial record.

Follow-up

Pregnancy outcomes will be measured at 10 months, and infants will be followed for 3 years post-partum.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.